Navigation Links
Using biomarkers to identify and treat schizophrenia
Date:7/11/2012

In the current online issue of PLoS ONE, researchers at the University of California, San Diego School of Medicine say they have identified a set of laboratory-based biomarkers that can be useful for understanding brain-based abnormalities in schizophrenia. The measurements, known as endophenotypes, could ultimately be a boon to clinicians who sometimes struggle to recognize and treat the complex and confounding mental disorder.

"A major problem in psychiatry is that there are currently no laboratory tests that aid in diagnosis, guide treatment decisions or help predict treatment response or outcomes," said Gregory A. Light, PhD, associate professor of psychiatry and the study's first author. "Diagnoses are currently based on a clinician's ability to make inferences about patients' inner experiences."

Diagnosing and treating schizophrenia is a particularly troubling challenge. The disorder, which affects about 1 percent of the U.S. population or roughly 3 million people, is characterized by a breakdown of normal thought processes and erratic, sometimes dangerous or harmful, behaviors.

"Schizophrenia is among the most severe and disabling conditions across all categories of medicine," said Light, who also directs the Mental Illness, Research, Education and Clinical Center at the San Diego VA Healthcare System.

The precise cause or causes of schizophrenia are not known, though there is a clear genetic component, with the disorder more common in some families.

Clinicians typically diagnose schizophrenia based upon inferences drawn from the patient's inner experiences. That is, their ability to describe what's happening inside their minds.

"But even the best clinicians struggle with diagnostic complexities based on sometimes fuzzy clinical phenomenology," said Light. The clinical challenge is compounded by the fact that "many schizophrenia patients have cognitive and functional impairments," said Light. They may not be able to reasonably explain how or what they think.

Light and colleagues investigated whether a select battery of neurophysiological and neurocognitive biomarkers could provide clinicians with reliable, accurate, long-term indicators of brain dysfunction, even when overt symptoms of the disorder were not apparent. These markers ranged from tests of attention and memory to physiological assessments of basic perceptual processes using scalp sensors to measure brain responses to simple sounds.

The researchers measured the biomarkers in 550 schizophrenia patients, and then re-tested 200 of the patients one year later. They found that most of the markers were significantly abnormal in schizophrenia patients, were relatively stable between the assessments and were not affected by modest fluctuations in clinical status of the patient.

Light said further research is required, including whether the endophenotypes can differentiate other psychiatric disorders, be used to anticipate patient response to different kinds of drugs or non-pharmacological interventions or even be used to predict which subjects are at high risk of developing a psychotic illness.

"We believe this paper is an important step towards validating laboratory-based biomarkers for use in future genomic and clinical treatment studies of schizophrenia," Light said.


'/>"/>
Contact: Scott LaFee
slafee@ucsd.edu
619-543-6163
University of California - San Diego
Source:Eurekalert

Related medicine news :

1. MU receives national award for using mind-body approach to improve health
2. More Teen Girls Using Contraceptives: CDC
3. Using Earplugs Eases ICU Patients Confusion: Study
4. 16 years old is peak risk for teens misusing prescription drugs
5. Kids Most Likely to Start Abusing Painkillers at 16: Study
6. Breathing during radiotherapy - how to hit the treatment target without causing collateral damage
7. Report using private health claims data shows prices are driving health spending growth
8. Type of viral infection of eye associated with disease causing blindness in the elderly
9. Hepatitis C Causing Liver Damage in Greater Numbers: Study
10. Pivotal role for proteins -- from helping turn carbs into energy to causing devastating disease
11. Population displacement during disasters predicted using mobile data
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/28/2016)... (PRWEB) , ... April 28, 2016 , ... ... the California Dental Association, today announced it has signed a letter of intent ... Corporation (DBC) and Northwest Dentists Insurance Company (NORDIC). , Started by dentists 36 ...
(Date:4/28/2016)... ... 28, 2016 , ... CastCoverz!, America’s #1 trusted brand for ... oldest waterproof cast protector . As the largest one-stop, orthopedic shop, CastCoverz! ... daily, night, weatherproof and waterproof covers for most orthopedic devices, including but not ...
(Date:4/28/2016)... ... April 28, 2016 , ... ... the organization’s most successful events, attracting medical professionals from around the globe who ... networking events. , Opening Ceremonies Sunday, April 17 included the introduction of the ...
(Date:4/28/2016)... ... April 28, 2016 , ... In many parts of the world, ... childhood mortality. This is particularly true in underdeveloped parts of Africa where clean sources ... New England’s campus in Tangier, Morocco, will examine this global health issue and consider ...
(Date:4/28/2016)... ... 28, 2016 , ... Cognizin® Citicoline is one of three ... the Healthy Ageing category, Cognizin® is being considered for this prestigious honor due ... include everything from antioxidants, lipids, proteins, and botanicals. NutraIngredients will choose a winner ...
Breaking Medicine News(10 mins):
(Date:4/28/2016)... Oramed Pharmaceuticals Inc. (NASDAQ: ... on the development of oral drug delivery systems, announced today ... conference, presented by Joseph Gunnar & Co. LLC, ... York . Nadav Kidron , CEO of Oramed, ... Presentation Details:   PIONEERS 2016, presented by ...
(Date:4/28/2016)... , April 28, 2016  ValGenesis, Inc., ... Management Solutions (VLMS) today announced that a ... for sufferers of chronic kidney failure has ... manage their corporate validation process. The global ... software solution to manage their validation processes ...
(Date:4/28/2016)... , April 28, 2016 ... H1 2016" is a report that provides an ... strengthen R&D pipelines by identifying new targets and ... Company Profiles discussed in this H1 2016 ... Riunite Srl, AbbVie Inc., Abiogen Pharma S.p.A., Ablynx ...
Breaking Medicine Technology: